mGluR8 Protein (Metabotropic Glutamate Receptor 8)

mGluR8 Protein (Metabotropic Glutamate Receptor 8)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2">mGluR8 (Metabotropic Glutamate Receptor 8)</th></tr>
<tr><td>Gene</td><td>[GRM8](/genes/grm8)</td></tr>
<tr><td>UniProt ID</td><td>[Q9URF5](https://www.uniprot.org/uniprot/Q9URF5)</td></tr>
<tr><td>Molecular Weight</td><td>98 kDa</td></tr>
<tr><td>Subcellular Localization</td><td>Presynaptic terminals, dendritic shafts</td></tr>
<tr><td>PDB Structures</td><td>6N4Z, 6N52</td></tr>
<tr><td>Family</td><td>Class C GPCR, Group III mGluRs</td></tr>
<tr><td>Ligand Affinity</td><td>Highest among Group III mGluRs (~15 μM)</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

mGluR8 (Metabotropic Glutamate Receptor 8) is a Group III metabotropic glutamate receptor with the highest glutamate affinity among the presynaptic Group III receptors. mGluR8 functions as an inhibitory autoreceptor that modulates glutamate release throughout the central nervous system, with particularly high expression in the olfactory bulb, cerebral cortex, and hippocampus. This receptor has emerged as a promising therapeutic target for Alzheimer's Disease, Parkinson's Disease, anxiety disorders, and epilepsy due to its neuroprotective and anticonvulsant properties. The receptor's widespread distribution and modulatory effects on synaptic transmission position it as a key regulator of excitatory signaling in both physiological and pathological states. [@corti2002][@ferraguti2008]

mGluR8 Protein (Metabotropic Glutamate Receptor 8)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2">mGluR8 (Metabotropic Glutamate Receptor 8)</th></tr>
<tr><td>Gene</td><td>[GRM8](/genes/grm8)</td></tr>
<tr><td>UniProt ID</td><td>[Q9URF5](https://www.uniprot.org/uniprot/Q9URF5)</td></tr>
<tr><td>Molecular Weight</td><td>98 kDa</td></tr>
<tr><td>Subcellular Localization</td><td>Presynaptic terminals, dendritic shafts</td></tr>
<tr><td>PDB Structures</td><td>6N4Z, 6N52</td></tr>
<tr><td>Family</td><td>Class C GPCR, Group III mGluRs</td></tr>
<tr><td>Ligand Affinity</td><td>Highest among Group III mGluRs (~15 μM)</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

mGluR8 (Metabotropic Glutamate Receptor 8) is a Group III metabotropic glutamate receptor with the highest glutamate affinity among the presynaptic Group III receptors. mGluR8 functions as an inhibitory autoreceptor that modulates glutamate release throughout the central nervous system, with particularly high expression in the olfactory bulb, cerebral cortex, and hippocampus. This receptor has emerged as a promising therapeutic target for Alzheimer's Disease, Parkinson's Disease, anxiety disorders, and epilepsy due to its neuroprotective and anticonvulsant properties. The receptor's widespread distribution and modulatory effects on synaptic transmission position it as a key regulator of excitatory signaling in both physiological and pathological states. [@corti2002][@ferraguti2008]

Structure and Molecular Architecture

mGluR8 shares the characteristic Class C GPCR architecture but has distinct structural features that contribute to its high ligand affinity:[@niswender2016]

Domain Organization

• Venus Flytrap Domain (VFD): The extracellular N-terminal domain that binds glutamate. mGluR8 has higher glutamate affinity compared to other Group III receptors due to distinct binding pocket architecture.
• Cysteine-Rich Domain (CRD): Connects the VFD to the transmembrane domain. This domain influences receptor activation and allosteric modulation.
• Seven-Transmembrane Domain (7TM): The transmembrane region (TM1-TM7) that couples to Gi/o proteins. Contains allosteric binding sites for modulators.
• C-terminal Tail: Intracellular domain with phosphorylation sites and PDZ-binding motifs that direct subcellular localization and protein interactions.

Structural Basis for High Affinity

mGluR8's higher glutamate affinity compared to mGluR4 and mGluR7 results from:

• Optimized binding pocket residues that form more stable hydrogen bonds with glutamate
• Slower off-rate kinetics for glutamate dissociation
• More favorable binding energy for the ligand-receptor interaction
• Distinct conformational states that stabilize the active form

Dimer Structure

Like other mGluRs, mGluR8 functions as an obligate homodimer. The dimer interface is in the VFD, and each monomer can bind glutamate independently, though there is evidence of cooperative activation between subunits.

Normal Physiological Function

mGluR8 plays critical roles in regulating synaptic transmission and neuronal excitability:[@linden2005][@schaffhauser2003]

Presynaptic Autoreceptor Function

• Gi/o protein signaling
• Voltage-gated calcium channel inhibition
• GIRK channel activation
• Direct inhibition of vesicle release machinery

Signaling Pathways

Glutamate → mGluR8 → Gi/o protein →
↓ cAMP → PKA inhibition
↓ VGCC inhibition → ↓ Ca²⁺ entry
↓ GIRK activation → hyperpolarization
↓ Synaptic vesicle release
↓ MAPK/ERK signaling
↓ PI3K/AKT signaling

Brain Distribution

• Highest expression: Olfactory bulb, cerebral cortex (layers II-III), hippocampus (CA1)
• Moderate expression: Basal ganglia (striatum, globus pallidus), thalamus, amygdala, cerebellum
• Cellular localization: Predominantly presynaptic on glutamatergic terminals
• Subcellular localization: Active zones, perisynaptic regions

Physiological Roles

• Synaptic plasticity: Modulates both LTP and LTD
• Learning and memory: Hippocampal mGluR8 contributes to spatial memory
• Anxiety and fear: Amygdala mGluR8 regulates fear responses
• Motor control: Basal ganglia mGluR8 influences motor learning
• Sensory processing: High expression in olfactory bulb for odor discrimination
• Seizure threshold: mGluR8 activation raises seizure threshold

Role in Neurodegenerative Diseases

Alzheimer's Disease

mGluR8 has emerging therapeutic relevance in AD:[@liu2019]

Pathogenic mechanisms:

• Excitotoxicity: Reduced mGluR8 signaling may contribute to excessive glutamate and excitotoxic damage
• Neuroinflammation: mGluR8 modulates microglial activation and cytokine release
• Synaptic dysfunction: Altered mGluR8 expression in AD brain contributes to synaptic loss

• mGluR8 activation reduces neuroinflammation in AD models
• Improves cognitive function in AD animal models
• Provides neuroprotection against Aβ toxicity
• May reduce excitotoxic damage

• Inhibits microglial pro-inflammatory activation
• Reduces excessive glutamate release
• Activates neuroprotective signaling (PI3K/AKT, MAPK/ERK)
• Preserves synaptic structure and function

Parkinson's Disease

mGluR8 offers neuroprotection in PD models:[@gu2015][@wang2017]

Motor symptoms:

• Modulates striatal glutamate release
• Influences basal ganglia circuit function
• May reduce motor complications

• Protects dopaminergic neurons in substantia nigra
• Reduces excitotoxic damage
• Modulates neuroinflammation
• Preserves mitochondrial function

Epilepsy and Seizure Disorders

mGluR8 is a validated anticonvulsant target:

Mechanisms:

• Reduces excessive glutamatergic transmission
• Raises seizure threshold
• Modulates seizure spread
• Limits excitotoxicity during seizures

• mGluR8 agonists show anticonvulsant effects
• Works synergistically with other antiepileptic drugs
• May address drug-resistant epilepsy

Anxiety and Mood Disorders

mGluR8 modulates anxiety-related behaviors:[@fendt2017]

• High expression in amygdala and hippocampus
• mGluR8 agonists show anxiolytic effects
• No sedation at effective doses
• May also have antidepressant properties

Neuroprotection Beyond Specific Diseases

mGluR8 provides broad neuroprotection through:

• Excitotoxicity prevention: Reduces excessive glutamate signaling
• Anti-inflammatory effects: Modulates microglial activation
• Mitochondrial protection: Preserves neuronal energy metabolism
• Anti-apoptotic signaling: Activates survival pathways

Protein Interactions

| Interacting Partner | Interaction Type | Functional Significance |
|---------------------|------------------|------------------------|
| GRM8 (homodimer) | Receptor dimerization | Functional signaling unit |
| PICK1 | PDZ domain | Presynaptic targeting |
| PKC | Phosphorylation | Receptor desensitization |
| GRIP1/2 | PDZ domain | Scaffold interactions |
| CACNA1A/B | Channel modulation | Calcium regulation |
| GIRK channels | G-protein activation | Hyperpolarization |
| Homer proteins | Scaffold | Synaptic anchoring |
| Caveolin-1 | Lipid rafts | Membrane organization |

Therapeutic Targeting

Drug Development Status

| Compound | Type | Target | Status | Indication |
|----------|------|--------|--------|------------|
| AZD-8529 | PAM | mGluR8 | Phase I | Anxiety, cognition |
| LY-487,379 | Agonist | mGluR8 | Research | Anticonvulsant |
| AMN082 | Agonist | mGluR8 | Research | Tool compound |
| VU0415376 | PAM | mGluR8 | Preclinical | CNS disorders |
| DSP-004 | Agonist | mGluR8 | Research | Tool compound |

Therapeutic Advantages

Challenges

• Receptor desensitization: Prolonged activation can lead to desensitization
• Selectivity: Achieving mGluR8-specific effects
• Dose optimization: Balancing efficacy with side effects
• Behavioral effects: Some mGluR8 modulators affect exploratory behavior

Key Publications

See Also

• [GRM8 Gene](/genes/grm8)
• [mGluR7 (GRM7)](/proteins/grm7-protein)
• [mGluR4 (GRM4)](/proteins/grm4-protein)
• [Glutamate Signaling](/mechanisms/glutamate-signaling)
• [Glutamate Excitotoxicity](/mechanisms/glutamate-excitotoxicity)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Epilepsy](/diseases/epilepsy)
• [Anxiety Disorders](/diseases/anxiety-disorders)

References